COVID-19 Clinical Trial
Official title:
Safety and Efficiency of Mesenchymal Stem Cell in Treating Pneumonia Patients Infected With COVID-19
The SARS-CoV-2 infection caused clusters of severe respiratory illness similar to severe acute respiratory syndrome coronavirus and was associated with ICU admission and high mortality. There is no confirmed antivirus therapy for people infected SARS-CoV-2, most of them should receive supportive care to help relieve symptoms. For severe cases, treatment should include care to support vital organ functions. This clinical trial is to inspect the safety and efficiency of Mesenchymal Stem Cells (MSCs) therapy for pneumonia patients infected with SARS-CoV-2.
SARS-CoV-2 infection has become an urgent public health event in China. As of 24:00 on
January 26, 2020, there are 2744 confirmed cases and 461 severe cases in China, the number is
still increasing. There is currently no vaccine and no specific antiviral treatment
recommended for SARS-CoV-2 infection. About 20% of the patients were severe and some died of
respiratory failure or multiple organ failure. Therefore, it is urgent to find a safe and
effective therapeutic approach to pneumonia patients infected with SARS-CoV-2.
In the last year, the promising features of mesenchymal stem cells (MSCs), including their
regenerative properties and ability to differentiate into diverse cell lineages, have
generated great interest among researchers whose work has offered intriguing perspectives on
cell-based therapies for various diseases. These findings seem to highlight that the
beneficial effect of MSC-based treatment could be principally due by the immunomodulation and
regenerative potential of these cells. The investigators found that infusions of UC-MSC
significantly improved liver function in decompensated liver cirrhosis and primary biliary
cirrhosis (PBC) patients, increased the survival rate in acute-on-chronic liver failure
(ACLF) patients . MSCs could significantly reduce the pathological changes of lung and
inhibit the cell-mediated immune inflammatory response induced by influenza virus in animal
model .
The purpose of this study is to investigate safety and efficiency of MSCs in treating
pneumonia patients infected with SARS-CoV-2. This multi-center trial will recruit 20
patients. 10 patients received i.v. transfusion one round (3 times) of 3.0*10E7 cells of MSCs
as the treated group, all of them received the conventional treatment. In addition, the equal
10 patients received conventional treatment were used as control. The clinical symptoms,
pulmonary imaging, side effects, 28-days mortality, immunological characteristics (immune
cells, inflammatory factors, etc.) will be evaluated during the 180 days follow up.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Withdrawn |
NCT06065033 -
Exercise Interventions in Post-acute Sequelae of Covid-19
|
N/A | |
| Completed |
NCT06267534 -
Mindfulness-based Mobile Applications Program
|
N/A | |
| Completed |
NCT05047601 -
A Study of a Potential Oral Treatment to Prevent COVID-19 in Adults Who Are Exposed to Household Member(s) With a Confirmed Symptomatic COVID-19 Infection
|
Phase 2/Phase 3 | |
| Recruiting |
NCT04481633 -
Efficacy of Pre-exposure Treatment With Hydroxy-Chloroquine on the Risk and Severity of COVID-19 Infection
|
N/A | |
| Recruiting |
NCT05323760 -
Functional Capacity in Patients Post Mild COVID-19
|
N/A | |
| Completed |
NCT04612972 -
Efficacy, Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccines (Vero Cell) to Prevent COVID-19 in Healthy Adult Population In Peru Healthy Adult Population In Peru
|
Phase 3 | |
| Completed |
NCT04537949 -
A Trial Investigating the Safety and Effects of One BNT162 Vaccine Against COVID-19 in Healthy Adults
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05494424 -
Cognitive Rehabilitation in Post-COVID-19 Condition
|
N/A | |
| Active, not recruiting |
NCT06039449 -
A Study to Investigate the Prevention of COVID-19 withVYD222 in Adults With Immune Compromise and in Participants Aged 12 Years or Older Who Are at Risk of Exposure to SARS-CoV-2
|
Phase 3 | |
| Enrolling by invitation |
NCT05589376 -
You and Me Healthy
|
||
| Completed |
NCT05158816 -
Extracorporal Membrane Oxygenation for Critically Ill Patients With COVID-19
|
||
| Recruiting |
NCT04341506 -
Non-contact ECG Sensor System for COVID19
|
||
| Completed |
NCT04512079 -
FREEDOM COVID-19 Anticoagulation Strategy
|
Phase 4 | |
| Completed |
NCT04384445 -
Zofin (Organicell Flow) for Patients With COVID-19
|
Phase 1/Phase 2 | |
| Completed |
NCT05975060 -
A Study to Evaluate the Safety and Immunogenicity of an (Omicron Subvariant) COVID-19 Vaccine Booster Dose in Previously Vaccinated Participants and Unvaccinated Participants.
|
Phase 2/Phase 3 | |
| Active, not recruiting |
NCT05542862 -
Booster Study of SpikoGen COVID-19 Vaccine
|
Phase 3 | |
| Withdrawn |
NCT05621967 -
Phonation Therapy to Improve Symptoms and Lung Physiology in Patients Referred for Pulmonary Rehabilitation
|
N/A | |
| Terminated |
NCT05487040 -
A Study to Measure the Amount of Study Medicine in Blood in Adult Participants With COVID-19 and Severe Kidney Disease
|
Phase 1 | |
| Terminated |
NCT04498273 -
COVID-19 Positive Outpatient Thrombosis Prevention in Adults Aged 40-80
|
Phase 3 | |
| Active, not recruiting |
NCT06033560 -
The Effect of Non-invasive Respiratory Support on Outcome and Its Risks in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-COV-2)-Related Hypoxemic Respiratory Failure
|